Cardiovascular outcome trials in patients with chronic kidney disease: Challenges associated with selection of patients and endpoints

Patrick Rossignol, Rajiv Agarwal, Bernard Canaud, Alan Charney, Gilles Chatellier, Jonathan C. Craig, William C. Cushman, Ronald T. Gansevoort, Bengt Fellström, Dahlia Garza, Nicolas Guzman, Frank A. Holtkamp, Gerard M. London, Ziad A. Massy, Alexandre Mebazaa, Peter G.M. Mol, Marc A. Pfeffer, Yves Rosenberg, Luis M. Ruilope, Jonathan SeltzerAmil M. Shah, Salim Shah, Bhupinder Singh, Bergur V. Stefánsson, Norman Stockbridge, Wendy Gattis Stough, Kristian Thygesen, Michael Walsh, Christoph Wanner, David G. Warnock, Christopher S. Wilcox, Janet Wittes, Bertram Pitt, Aliza Thompson, Faiez Zannad

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Although cardiovascular disease is a major health burden for patients with chronic kidney disease, most cardiovascular outcome trials have excluded patients with advanced chronic kidney disease. Moreover, the major cardiovascular outcome trials that have been conducted in patients with end-stage renal disease have not demonstrated a treatment benefit. Thus, clinicians have limited evidence to guide the management of cardiovascular disease in patients with chronic kidney disease, particularly those on dialysis. Several factors contribute to both the paucity of trials and the apparent lack of observed treatment effect in completed studies. Challenges associated with conducting trials in this population include patient heterogeneity, complexity of renal pathophysiology and its interaction with cardiovascular disease, and competing risks for death. The Investigator Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT), an international organization of academic cardiovascular and renal clinical trialists, held a meeting of regulators and experts in nephrology, cardiology, and clinical trial methodology. The group identified several research priorities, summarized in this paper, that should be pursued to advance the field towards achieving improved cardiovascular outcomes for these patients. Cardiovascular and renal clinical trialists must partner to address the uncertainties in the field through collaborative research and design clinical trials that reflect the specific needs of the chronic and end-stage kidney disease populations, with the shared goal of generating robust evidence to guide the management of cardiovascular disease in patients with kidney disease.

Original languageEnglish (US)
Pages (from-to)880-886
Number of pages7
JournalEuropean Heart Journal
Volume40
Issue number11
DOIs
StatePublished - Mar 14 2019

Fingerprint

Chronic Renal Insufficiency
Patient Selection
Cardiovascular Diseases
Kidney
Chronic Kidney Failure
Clinical Trials
Nephrology
Kidney Diseases
Cardiology
Population
Uncertainty
Dialysis
Research Design
Research Personnel
Health
Therapeutics
Research

Keywords

  • Cardiovascular diseases
  • Chronic kidney failure
  • Chronic renal insufficiency
  • Clinical trials as topic

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cardiovascular outcome trials in patients with chronic kidney disease : Challenges associated with selection of patients and endpoints. / Rossignol, Patrick; Agarwal, Rajiv; Canaud, Bernard; Charney, Alan; Chatellier, Gilles; Craig, Jonathan C.; Cushman, William C.; Gansevoort, Ronald T.; Fellström, Bengt; Garza, Dahlia; Guzman, Nicolas; Holtkamp, Frank A.; London, Gerard M.; Massy, Ziad A.; Mebazaa, Alexandre; Mol, Peter G.M.; Pfeffer, Marc A.; Rosenberg, Yves; Ruilope, Luis M.; Seltzer, Jonathan; Shah, Amil M.; Shah, Salim; Singh, Bhupinder; Stefánsson, Bergur V.; Stockbridge, Norman; Stough, Wendy Gattis; Thygesen, Kristian; Walsh, Michael; Wanner, Christoph; Warnock, David G.; Wilcox, Christopher S.; Wittes, Janet; Pitt, Bertram; Thompson, Aliza; Zannad, Faiez.

In: European Heart Journal, Vol. 40, No. 11, 14.03.2019, p. 880-886.

Research output: Contribution to journalArticle

Rossignol, P, Agarwal, R, Canaud, B, Charney, A, Chatellier, G, Craig, JC, Cushman, WC, Gansevoort, RT, Fellström, B, Garza, D, Guzman, N, Holtkamp, FA, London, GM, Massy, ZA, Mebazaa, A, Mol, PGM, Pfeffer, MA, Rosenberg, Y, Ruilope, LM, Seltzer, J, Shah, AM, Shah, S, Singh, B, Stefánsson, BV, Stockbridge, N, Stough, WG, Thygesen, K, Walsh, M, Wanner, C, Warnock, DG, Wilcox, CS, Wittes, J, Pitt, B, Thompson, A & Zannad, F 2019, 'Cardiovascular outcome trials in patients with chronic kidney disease: Challenges associated with selection of patients and endpoints', European Heart Journal, vol. 40, no. 11, pp. 880-886. https://doi.org/10.1093/eurheartj/ehx209
Rossignol, Patrick ; Agarwal, Rajiv ; Canaud, Bernard ; Charney, Alan ; Chatellier, Gilles ; Craig, Jonathan C. ; Cushman, William C. ; Gansevoort, Ronald T. ; Fellström, Bengt ; Garza, Dahlia ; Guzman, Nicolas ; Holtkamp, Frank A. ; London, Gerard M. ; Massy, Ziad A. ; Mebazaa, Alexandre ; Mol, Peter G.M. ; Pfeffer, Marc A. ; Rosenberg, Yves ; Ruilope, Luis M. ; Seltzer, Jonathan ; Shah, Amil M. ; Shah, Salim ; Singh, Bhupinder ; Stefánsson, Bergur V. ; Stockbridge, Norman ; Stough, Wendy Gattis ; Thygesen, Kristian ; Walsh, Michael ; Wanner, Christoph ; Warnock, David G. ; Wilcox, Christopher S. ; Wittes, Janet ; Pitt, Bertram ; Thompson, Aliza ; Zannad, Faiez. / Cardiovascular outcome trials in patients with chronic kidney disease : Challenges associated with selection of patients and endpoints. In: European Heart Journal. 2019 ; Vol. 40, No. 11. pp. 880-886.
@article{357e1bc711fe422aae6f920faac12de6,
title = "Cardiovascular outcome trials in patients with chronic kidney disease: Challenges associated with selection of patients and endpoints",
abstract = "Although cardiovascular disease is a major health burden for patients with chronic kidney disease, most cardiovascular outcome trials have excluded patients with advanced chronic kidney disease. Moreover, the major cardiovascular outcome trials that have been conducted in patients with end-stage renal disease have not demonstrated a treatment benefit. Thus, clinicians have limited evidence to guide the management of cardiovascular disease in patients with chronic kidney disease, particularly those on dialysis. Several factors contribute to both the paucity of trials and the apparent lack of observed treatment effect in completed studies. Challenges associated with conducting trials in this population include patient heterogeneity, complexity of renal pathophysiology and its interaction with cardiovascular disease, and competing risks for death. The Investigator Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT), an international organization of academic cardiovascular and renal clinical trialists, held a meeting of regulators and experts in nephrology, cardiology, and clinical trial methodology. The group identified several research priorities, summarized in this paper, that should be pursued to advance the field towards achieving improved cardiovascular outcomes for these patients. Cardiovascular and renal clinical trialists must partner to address the uncertainties in the field through collaborative research and design clinical trials that reflect the specific needs of the chronic and end-stage kidney disease populations, with the shared goal of generating robust evidence to guide the management of cardiovascular disease in patients with kidney disease.",
keywords = "Cardiovascular diseases, Chronic kidney failure, Chronic renal insufficiency, Clinical trials as topic",
author = "Patrick Rossignol and Rajiv Agarwal and Bernard Canaud and Alan Charney and Gilles Chatellier and Craig, {Jonathan C.} and Cushman, {William C.} and Gansevoort, {Ronald T.} and Bengt Fellstr{\"o}m and Dahlia Garza and Nicolas Guzman and Holtkamp, {Frank A.} and London, {Gerard M.} and Massy, {Ziad A.} and Alexandre Mebazaa and Mol, {Peter G.M.} and Pfeffer, {Marc A.} and Yves Rosenberg and Ruilope, {Luis M.} and Jonathan Seltzer and Shah, {Amil M.} and Salim Shah and Bhupinder Singh and Stef{\'a}nsson, {Bergur V.} and Norman Stockbridge and Stough, {Wendy Gattis} and Kristian Thygesen and Michael Walsh and Christoph Wanner and Warnock, {David G.} and Wilcox, {Christopher S.} and Janet Wittes and Bertram Pitt and Aliza Thompson and Faiez Zannad",
year = "2019",
month = "3",
day = "14",
doi = "10.1093/eurheartj/ehx209",
language = "English (US)",
volume = "40",
pages = "880--886",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Cardiovascular outcome trials in patients with chronic kidney disease

T2 - Challenges associated with selection of patients and endpoints

AU - Rossignol, Patrick

AU - Agarwal, Rajiv

AU - Canaud, Bernard

AU - Charney, Alan

AU - Chatellier, Gilles

AU - Craig, Jonathan C.

AU - Cushman, William C.

AU - Gansevoort, Ronald T.

AU - Fellström, Bengt

AU - Garza, Dahlia

AU - Guzman, Nicolas

AU - Holtkamp, Frank A.

AU - London, Gerard M.

AU - Massy, Ziad A.

AU - Mebazaa, Alexandre

AU - Mol, Peter G.M.

AU - Pfeffer, Marc A.

AU - Rosenberg, Yves

AU - Ruilope, Luis M.

AU - Seltzer, Jonathan

AU - Shah, Amil M.

AU - Shah, Salim

AU - Singh, Bhupinder

AU - Stefánsson, Bergur V.

AU - Stockbridge, Norman

AU - Stough, Wendy Gattis

AU - Thygesen, Kristian

AU - Walsh, Michael

AU - Wanner, Christoph

AU - Warnock, David G.

AU - Wilcox, Christopher S.

AU - Wittes, Janet

AU - Pitt, Bertram

AU - Thompson, Aliza

AU - Zannad, Faiez

PY - 2019/3/14

Y1 - 2019/3/14

N2 - Although cardiovascular disease is a major health burden for patients with chronic kidney disease, most cardiovascular outcome trials have excluded patients with advanced chronic kidney disease. Moreover, the major cardiovascular outcome trials that have been conducted in patients with end-stage renal disease have not demonstrated a treatment benefit. Thus, clinicians have limited evidence to guide the management of cardiovascular disease in patients with chronic kidney disease, particularly those on dialysis. Several factors contribute to both the paucity of trials and the apparent lack of observed treatment effect in completed studies. Challenges associated with conducting trials in this population include patient heterogeneity, complexity of renal pathophysiology and its interaction with cardiovascular disease, and competing risks for death. The Investigator Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT), an international organization of academic cardiovascular and renal clinical trialists, held a meeting of regulators and experts in nephrology, cardiology, and clinical trial methodology. The group identified several research priorities, summarized in this paper, that should be pursued to advance the field towards achieving improved cardiovascular outcomes for these patients. Cardiovascular and renal clinical trialists must partner to address the uncertainties in the field through collaborative research and design clinical trials that reflect the specific needs of the chronic and end-stage kidney disease populations, with the shared goal of generating robust evidence to guide the management of cardiovascular disease in patients with kidney disease.

AB - Although cardiovascular disease is a major health burden for patients with chronic kidney disease, most cardiovascular outcome trials have excluded patients with advanced chronic kidney disease. Moreover, the major cardiovascular outcome trials that have been conducted in patients with end-stage renal disease have not demonstrated a treatment benefit. Thus, clinicians have limited evidence to guide the management of cardiovascular disease in patients with chronic kidney disease, particularly those on dialysis. Several factors contribute to both the paucity of trials and the apparent lack of observed treatment effect in completed studies. Challenges associated with conducting trials in this population include patient heterogeneity, complexity of renal pathophysiology and its interaction with cardiovascular disease, and competing risks for death. The Investigator Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT), an international organization of academic cardiovascular and renal clinical trialists, held a meeting of regulators and experts in nephrology, cardiology, and clinical trial methodology. The group identified several research priorities, summarized in this paper, that should be pursued to advance the field towards achieving improved cardiovascular outcomes for these patients. Cardiovascular and renal clinical trialists must partner to address the uncertainties in the field through collaborative research and design clinical trials that reflect the specific needs of the chronic and end-stage kidney disease populations, with the shared goal of generating robust evidence to guide the management of cardiovascular disease in patients with kidney disease.

KW - Cardiovascular diseases

KW - Chronic kidney failure

KW - Chronic renal insufficiency

KW - Clinical trials as topic

UR - http://www.scopus.com/inward/record.url?scp=85062883461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062883461&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehx209

DO - 10.1093/eurheartj/ehx209

M3 - Article

C2 - 28431138

AN - SCOPUS:85062883461

VL - 40

SP - 880

EP - 886

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 11

ER -